2025 Universal Registration Document

5. 2025 Consolidated Financial Statements

Fair value hierarchy
€ millions        
31 December 2024 Level 1 Level 2 Level 3 Total fair value
ASSETS AT FAIR VALUE ASSETS AT FAIR VALUE

 

 

ASSETS AT FAIR VALUE

 

 

ASSETS AT FAIR VALUE

 

 

ASSETS AT FAIR VALUE

 

 

Foreign exchange derivatives

Foreign exchange derivatives

 

 

Foreign exchange derivatives

 

150.1

Foreign exchange derivatives

 

 

Foreign exchange derivatives

 

150.1

Sanofi shares

Sanofi shares

 

11,082.6

Sanofi shares

 

 

Sanofi shares

 

 

Sanofi shares

 

11,082.6

Galderma shares

Galderma shares

 

2,550.0

Galderma shares

 

 

Galderma shares

 

 

Galderma shares

 

2,550.0

Other securities

Other securities

 

23.2

Other securities

 

 

Other securities

 

554.6

Other securities

 

577.8

Marketable securities

Marketable securities

 

1,829.3

Marketable securities

 

 

Marketable securities

 

 

Marketable securities

 

1,829.3

TOTAL ASSETS AT FAIR VALUE

TOTAL ASSETS AT FAIR VALUE

 

15,485.1

TOTAL ASSETS AT FAIR VALUE

 

150.1

TOTAL ASSETS AT FAIR VALUE

 

554.6

TOTAL ASSETS AT FAIR VALUE

 

16,189.8

LIABILITIES AT FAIR VALUE LIABILITIES AT FAIR VALUE

 

 

LIABILITIES AT FAIR VALUE

 

 

LIABILITIES AT FAIR VALUE

 

 

LIABILITIES AT FAIR VALUE

 

 

Foreign exchange derivatives

Foreign exchange derivatives

 

 

Foreign exchange derivatives

 

232.2

Foreign exchange derivatives

 

 

Foreign exchange derivatives

 

232.2

TOTAL LIABILITIES AT FAIR VALUE

TOTAL LIABILITIES AT FAIR VALUE

 

TOTAL LIABILITIES AT FAIR VALUE

 

232.2

TOTAL LIABILITIES AT FAIR VALUE

 

TOTAL LIABILITIES AT FAIR VALUE

 

232.2

Fair value hierarchy
€ millions        
31 December 2023 Level 1 Level 2 Level 3 Total fair value
ASSETS AT FAIR VALUE ASSETS AT FAIR VALUE

 

 

ASSETS AT FAIR VALUE

 

 

ASSETS AT FAIR VALUE

 

 

ASSETS AT FAIR VALUE

 

 

Foreign exchange derivatives

Foreign exchange derivatives

 

 

Foreign exchange derivatives

 

177.7

Foreign exchange derivatives

 

 

Foreign exchange derivatives

 

177.7

Sanofi shares

Sanofi shares

 

10,612.1

Sanofi shares

 

 

Sanofi shares

 

 

Sanofi shares

 

10,612.1

Other securities

Other securities

 

60.8

Other securities

 

 

Other securities

 

457.3

Other securities

 

518.1

Marketable securities

Marketable securities

 

624.1

Marketable securities

 

 

Marketable securities

 

 

Marketable securities

 

624.1

TOTAL ASSETS AT FAIR VALUE

TOTAL ASSETS AT FAIR VALUE

 

11,297.0

TOTAL ASSETS AT FAIR VALUE

 

177.7

TOTAL ASSETS AT FAIR VALUE

 

457.3

TOTAL ASSETS AT FAIR VALUE

 

11,932.0

LIABILITIES AT FAIR VALUE LIABILITIES AT FAIR VALUE

 

 

LIABILITIES AT FAIR VALUE

 

 

LIABILITIES AT FAIR VALUE

 

 

LIABILITIES AT FAIR VALUE

 

 

Foreign exchange derivatives

Foreign exchange derivatives

 

 

Foreign exchange derivatives

 

127.1

Foreign exchange derivatives

 

 

Foreign exchange derivatives

 

127.1

TOTAL LIABILITIES AT FAIR VALUE

TOTAL LIABILITIES AT FAIR VALUE

 

TOTAL LIABILITIES AT FAIR VALUE

 

127.1

TOTAL LIABILITIES AT FAIR VALUE

 

TOTAL LIABILITIES AT FAIR VALUE

 

127.1

10.9 Offsetting financial assets and financial liabilities

Financial assets and liabilities resulting from foreign exchange and/or interest rate hedging transactions entered into with the Group’s counterparty banks are not offset in the balance sheet since they are FBF (French Banking Federation) or ISDA (International Swaps and Derivatives Association) agreements that only provide for offsetting in the event of default by one of the parties to the agreement. Accordingly, they do not meet the offsetting criteria set out in IAS 32.

Had the agreements been offset at the level of each counterparty bank, assets and liabilities would have decreased by €136.4 million, €137.8 million and €105.5 million respectively in 2025, 2024 and 2023.

Note 11 Equity – Earnings per share

11.1 Share capital and additional paid in capital

Share capital consists of 533,783,028 shares with a par value of €0.20 at 31 December 2025 following the issue of 279,923 shares for the employee shareholding plan and 547,720 free shares and the cancellation of 1,356,636 shares.

Share capital consisted of 534,312,021 shares with a par value of €0.20 at 31 December 2024 following the issue of 230,423 shares for the employee shareholding plan and 664,680 free shares and the cancellation of 1,308,557 shares.

Share capital consisted of 534,725,475 shares with a par value of €0.20 at 31 December 2023, following the issue of 34,020 shares for the employee shareholding plan and 776,525 free shares and the cancellation of 1,271,632 shares.

11.2 Treasury shares
Accounting principles

Treasury shares are recorded at acquisition cost and deducted from equity. Capital gains/losses on disposal of these items net of tax are charged directly to equity and do not contribute to profit for the financial year.